HK1047102A1 - Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists - Google Patents

Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists

Info

Publication number
HK1047102A1
HK1047102A1 HK02108677.1A HK02108677A HK1047102A1 HK 1047102 A1 HK1047102 A1 HK 1047102A1 HK 02108677 A HK02108677 A HK 02108677A HK 1047102 A1 HK1047102 A1 HK 1047102A1
Authority
HK
Hong Kong
Prior art keywords
aryl
production
carboxylic acid
acid derivatives
receptor antagonists
Prior art date
Application number
HK02108677.1A
Other languages
Chinese (zh)
Inventor
W‧阿穆伯格
G‧凱茨舒
Original Assignee
巴斯福股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 巴斯福股份公司 filed Critical 巴斯福股份公司
Publication of HK1047102A1 publication Critical patent/HK1047102A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02108677.1A 1999-06-01 2002-11-29 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists HK1047102A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19924892A DE19924892A1 (en) 1999-06-01 1999-06-01 New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their production and use as endothelin receptor antagonists
PCT/EP2000/004571 WO2000073276A2 (en) 1999-06-01 2000-05-19 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
HK1047102A1 true HK1047102A1 (en) 2003-02-07

Family

ID=7909761

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108677.1A HK1047102A1 (en) 1999-06-01 2002-11-29 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists

Country Status (20)

Country Link
EP (1) EP1181281A2 (en)
JP (1) JP2003500476A (en)
KR (1) KR20020006049A (en)
CN (1) CN1359376A (en)
AR (1) AR022047A1 (en)
AU (1) AU765345B2 (en)
BG (1) BG106154A (en)
BR (1) BR0011105A (en)
CA (1) CA2375666A1 (en)
CZ (1) CZ20014312A3 (en)
DE (1) DE19924892A1 (en)
HK (1) HK1047102A1 (en)
HU (1) HUP0201387A3 (en)
IL (1) IL146800A0 (en)
MX (1) MXPA01012284A (en)
NO (1) NO20015762L (en)
PL (1) PL355112A1 (en)
SK (1) SK17552001A3 (en)
TR (1) TR200103475T2 (en)
WO (1) WO2000073276A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011147232A (en) * 2009-04-22 2013-05-27 Астеллас Фарма Инк. CARBONIC ACID DERIVATIVE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901416T2 (en) * 1996-12-18 1999-08-23 Basf Aktiengesellschaft Heterocyclic carbonicacyte térevleri.
DE19726146A1 (en) * 1997-06-19 1998-12-24 Basf Ag New ß-amino and ß-azidopcarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists
TR200000602T2 (en) * 1997-09-04 2000-12-21 Basf Aktiengesellschaft New carbonic acid derivatives, their production and uses.
DE19806438A1 (en) * 1998-02-17 1999-08-19 Basf Ag New pyrimidinyloxy-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiac insufficiency, restenosis, hypertension, kidney failure, asthma and prostate cancer
DE19809144A1 (en) * 1998-03-04 1999-09-09 Basf Ag New asymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed ET¶LAMBDA¶ / ET¶B¶ receptor antagonists
DE19836044A1 (en) * 1998-08-10 2000-02-17 Basf Ag New 2-(hetero)aryl-alkanoic acid derivatives, useful as mixed endothelin receptor antagonists, e.g. for treating cardiac insufficiency, restenosis, hypertension or prostate cancer

Also Published As

Publication number Publication date
KR20020006049A (en) 2002-01-18
MXPA01012284A (en) 2002-07-30
AR022047A1 (en) 2002-09-04
AU5395900A (en) 2000-12-18
CN1359376A (en) 2002-07-17
IL146800A0 (en) 2002-07-25
WO2000073276A3 (en) 2001-05-10
AU765345B2 (en) 2003-09-18
BG106154A (en) 2002-08-30
NO20015762L (en) 2001-12-13
NO20015762D0 (en) 2001-11-26
HUP0201387A2 (en) 2002-08-28
JP2003500476A (en) 2003-01-07
CA2375666A1 (en) 2000-12-07
WO2000073276A2 (en) 2000-12-07
SK17552001A3 (en) 2002-08-06
PL355112A1 (en) 2004-04-05
BR0011105A (en) 2002-03-05
TR200103475T2 (en) 2002-04-22
CZ20014312A3 (en) 2003-02-12
HUP0201387A3 (en) 2004-12-28
DE19924892A1 (en) 2000-12-07
EP1181281A2 (en) 2002-02-27

Similar Documents

Publication Publication Date Title
EG24136A (en) Piperazine derivatives useful as ccr5 antagonists
ZA200108867B (en) Piperidine derivatives useful as CCR5 antagonists.
HUP0201664A2 (en) Urea substituted imidazoquinolines
EP1206262A4 (en) Npy antagonists: spiroisoquinolinone derivatives
HUP0202202A3 (en) Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof
MXPA02008402A (en) Derivatives of quinoline as alpha-2 antagonists.
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
AU2001231730A1 (en) Piperidyl carboxylic acids as integrin antagonists
IL135347A0 (en) New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
AU2002220598A1 (en) Beta-amino acid derivatives as integrin receptor antagonists
IL145051A0 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
IL130251A0 (en) Heterocyclic carboxylic acid derivatives the production and use thereof as endothelin receptor antagonists
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
ZA985277B (en) Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists.
HK1047102A1 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
HU0001397D0 (en) 3-amino-3-arylpropan-1-ol derivatives, production and use thereof
IL137038A0 (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
IL143451A0 (en) NEW- β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
EP1169042A4 (en) Dibenzo-azepine derivatives as alpha v integrin receptor antagonists
AU2001268490A1 (en) Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
IL147666A0 (en) Novel carboxylic acid derivatives with 5, 6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
EP1202738A4 (en) Dihydropyrazine derivatives as npy antagonists
PL345998A1 (en) New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists
ZA991738B (en) Novel unsymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed et /et receptor antagonists.
ZA989923B (en) Novel carboxylic acid derivatives with amide side chains, their preparation and use as endothelin receptor antagonists.